Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-Protocol and statistical analysis plan

Research output: Contribution to journalJournal articleResearchpeer-review

  • Marie Warrer Petersen
  • Tine Sylvest Meyhoff
  • Marie Helleberg
  • Maj-Brit Norregaard Kjaer
  • Anders Granholm
  • Carl Johan Steensen Hjortso
  • Thomas Steen Jensen
  • Peter Buhl Hjortrup
  • Mik Wetterslev
  • Gitte Kingo Vesterlund
  • Lene Russell
  • Vibeke Lind Jorgensen
  • Klaus Tjelle
  • Thomas Mohr
  • Lone Musaeus Poulsen
  • Thomas Hildebrandt
  • Anders Moller
  • Christoffer Grant Solling
  • Anne Craveiro Brochner
  • Bodil Steen Rasmussen
  • Henrik Nielsen
  • Steffen Christensen
  • Thomas Strom
  • Maria Cronhjort
  • Rebecka Rubenson Wahlin
  • Stephan Jakob
  • Luca Cioccari
  • Balasubramanian Venkatesh
  • Naomi Hammond
  • Vivekanand Jha
  • Sheila Nainan Myatra
  • Christian Gluud

Introduction Severe acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease (COVID-19) with many patients developing hypoxic respiratory failure. Corticosteroids reduce the time on mechanical ventilation, length of stay in the intensive care unit and potentially also mortality in similar patient populations. However, corticosteroids have undesirable effects, including longer time to viral clearance. Clinical equipoise on the use of corticosteroids for COVID-19 exists. Methods The COVID STEROID trial is an international, randomised, stratified, blinded clinical trial. We will allocate 1000 adult patients with COVID-19 receiving >= 10 L/min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200 mg daily vs placebo (0.9% saline) for 7 days. The primary outcome is days alive without life support (ie mechanical ventilation, circulatory support, and renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions at day 14; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90, and 1 year; and health-related quality of life at 1 year. We will conduct the statistical analyses according to this protocol, including interim analyses for every 250 patients followed for 28 days. The primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95% confidence intervals. Discussion The COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia.

Original languageEnglish
JournalActa Anaesthesiologica Scandinavica
Issue number9
Pages (from-to)1365-1375
Number of pages11
Publication statusPublished - 2020

    Research areas


ID: 246779579